申请人:FIELD TRIP PSYCHEDELICS INC
公开号:WO2022000091A1
公开(公告)日:2022-01-06
The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.